AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Lexicon Pharmaceuticals, Inc.
Video analysis: LXRX
All videosNo video analysis for this stock yet. Request one from our team.
News: LXRX
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D, is the primary value driver; the pivotal SONATA-HCM Phase III readout is expected in 2027, and an NDA re-filing for T1D before year-end. Regulatory and commercialization risks arguably outweigh clinical risk, especially for T1D, as the company would have to commit considerable resources to commercialization to maximize the value of sotagliflozin.
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.01 per share a year ago.
